Literature DB >> 22842691

Evaluation of a cancer survivorship protocol: transitioning patients to survivors.

Kristin R Curcio1, Camille Lambe, Susan Schneider, Kalsoom Khan.   

Abstract

This article describes the implementation and evaluation of a survivorship protocol for cancer survivors to improve knowledge about their disease and decrease anxiety. The study included a convenience sample of 30 cancer survivors at an outpatient community cancer center in the southeastern United States following completion of acute oncology treatment. One month after the survivorship protocol was delivered, knowledge about diagnosis, treatments, recommended follow-up, signs of recurrence, and late side effects increased. Anxiety scores were lower one month after the intervention, and satisfaction with the protocol was high. The results demonstrated that the survivorship protocol is a feasible method of educating cancer survivors, supporting the Institute of Medicine's recommendation that strategies for delivering education to cancer survivors are important. Survivors have additional needs that must be addressed following treatment, and a survivorship protocol can provide the knowledge survivors need to participate in their own health care.

Entities:  

Mesh:

Year:  2012        PMID: 22842691     DOI: 10.1188/12.CJON.400-406

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  9 in total

1.  Development and evaluation of a survey to assess survivor knowledge change after survivorship care plans: WiSDOM-B (Wisconsin Survey of cancer DiagnOsis and Management in Breast cancer).

Authors:  Gabrielle B Rocque; Kari B Wisinski; Kevin A Buhr; Jamie L Froeschner; Nathan Jones; Sarah Donohue; Douglas Wiegmann; Mary E Sesto; Amye J Tevaarwerk
Journal:  J Cancer Educ       Date:  2014-06       Impact factor: 2.037

2.  Development and validation of an individualized survivorship care plan (ISCP) for women with endometrial cancer during the transition of the end of active treatment to the cancer survivorship.

Authors:  Johanne Hébert; Lise Fillion
Journal:  Can Oncol Nurs J       Date:  2017-02-01

3.  Assessment of the feasibility and acceptability, and pre-test of the utility of an individualized survivorship care plan (ISCP) for women with endometrial cancers during the transition of the end of active treatment to cancer survivorship.

Authors:  Johanne Hébert; Lise Fillion
Journal:  Can Oncol Nurs J       Date:  2017-05-01

4.  Developing personalized survivorship care pathways in the United States: Existing resources and remaining challenges.

Authors:  Caitlin B Biddell; Lisa P Spees; Deborah K Mayer; Stephanie B Wheeler; Justin G Trogdon; Jason Rotter; Sarah A Birken
Journal:  Cancer       Date:  2020-12-01       Impact factor: 6.860

Review 5.  A systematic review of barriers to optimal outpatient specialist services for individuals with prevalent chronic diseases: what are the unique and common barriers experienced by patients in high income countries?

Authors:  Elizabeth A Fradgley; Christine L Paul; Jamie Bryant
Journal:  Int J Equity Health       Date:  2015-06-09

6.  Are there opportunities to improve care as patients transition through the cancer care continuum? A scoping review protocol.

Authors:  Khara Sauro; Arjun Maini; Matthew Machan; Diane Lorenzetti; Shamir Chandarana; Joseph Dort
Journal:  BMJ Open       Date:  2021-01-25       Impact factor: 2.692

7.  Understanding the Post-Treatment Concerns of Cancer Survivors with Five Common Cancers: Exploring the Alberta Results from the Pan-Canadian Transitions Study.

Authors:  Claire Link; Andrea DeIure; Linda Watson
Journal:  Curr Oncol       Date:  2022-04-12       Impact factor: 3.109

Review 8.  A case of complicated survivorship care.

Authors:  Jean Rosiak; Candi Humphreys
Journal:  J Adv Pract Oncol       Date:  2014-01

9.  Existence of late-effects instruments for cancer survivors: A systematic review.

Authors:  Hillary Klonoff-Cohen; Mounika Polavarapu
Journal:  PLoS One       Date:  2020-02-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.